About: Trastuzumab/hyaluronidase

An Entity of Type: combination drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults. It is a combination of trastuzumab and hyaluronidase. The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity.

Property Value
dbo:abstract
  • Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults. It is a combination of trastuzumab and hyaluronidase. The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity. Trastuzumab/hyaluronidase was approved for medical use in the European Union in August 2013. Trastuzumab/hyaluronidase was approved for medical use in the United States in February 2019. (en)
dbo:alternativeName
  • Herceptin SC, Herceptin Hylecta (en)
dbo:casNumber
  • 180288-69-1
  • 757971-58-7
dbo:fdaUniiCode
  • 743QUY4VD8
  • P188ANX8CK
dbo:kegg
  • D11560
dbo:medlinePlus
  • a619041
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 64791009 (xsd:integer)
dbo:wikiPageLength
  • 10735 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1095855087 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • None (en)
dbp:casNumber
  • 180288 (xsd:integer)
  • 757971 (xsd:integer)
dbp:class
dbp:component
  • Hyaluronidase (en)
  • Trastuzumab (en)
dbp:kegg
  • D11560 (en)
dbp:legalAu
  • S4 (en)
dbp:legalCa
  • Rx-only (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalStatus
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:medlineplus
  • a619041 (en)
dbp:routesOfAdministration
dbp:tradename
  • Herceptin SC, Herceptin Hylecta (en)
dbp:type
  • combo (en)
dbp:unii
  • 743 (xsd:integer)
  • P188ANX8CK (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast cancer in adults. It is a combination of trastuzumab and hyaluronidase. The most common adverse reactions include fatigue, arthralgia, diarrhea, injection site reaction, upper respiratory tract infection, rash, myalgia, nausea, headache, edema, flushing, pyrexia, cough, and pain in extremity. (en)
rdfs:label
  • Trastuzumab/hyaluronidase (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License